"uuid:ID","text","name","sectionTitle","id","sectionNumber"
"582cb906-9cc4-4211-9f09-880c5cca004c","","ROOT","Root","NarrativeContent_1","0"
"ddcf265c-d1cc-4b4b-9ea6-e354d4213380","<div><usdm:ref klass=""StudyIdentifier"" id=""StudyIdentifier_1"" attribute=""studyIdentifier""/></div>","SECTION 1","PROTOCOL SUMMARY","NarrativeContent_2","1"
"3d95b9c9-1628-4afa-a604-17866332569a","<div></div>","SECTION 1.1","Protocol Synopsis","NarrativeContent_3","1.1"
"014b4b00-830b-41bd-9af4-d18ca17901ef","<div></div>","SECTION 1.2","Trial Schema","NarrativeContent_4","1.2"
"1a433e30-5cd0-4642-af0b-ed9b5b4c1953","<div></div>","SECTION 1.3","Schedule of Activities","NarrativeContent_5","1.3"
"a3ca6c71-0592-44e2-8247-892e41c14412","<div></div>","SECTION 2","INTRODUCTION","NarrativeContent_6","2"
"22bddaeb-ee5a-42c2-87fb-059e1486b881","<div></div>","SECTION 2.1","Purpose of Trial","NarrativeContent_7","2.1"
"198d8cac-399e-4910-b8b6-ad864dc97af1","<div></div>","SECTION 2.2","Summary of Benefits and Risks","NarrativeContent_8","2.2"
"dcd87edb-1330-449c-821e-69ec76100da2","<div></div>","SECTION 3","TRIAL OBJECTIVES, ENDPOINTS AND ESTIMANDS","NarrativeContent_9","3"
"eafe61a1-7e76-45fb-a90b-76b13dd2e3ef","<div><table>
  <tr>
    <th style=""vertical-align: top"">Primary Objective</th>
    <th style=""vertical-align: top"">Primary Endpoint</th>
  </tr>
  <tr>
    <td style=""vertical-align: top""><usdm:ref klass=""Objective"" namexref=""OBJ1"" attribute=""description""/></td>
    <td style=""vertical-align: top""><usdm:ref klass=""Endpoint"" id=""Endpoint_1"" attribute=""description""/></td>
  </tr>
</table></div>","SECTION 3.1","Primary Objectives","NarrativeContent_10","3.1"
"ef5770fa-a0a5-4669-a676-5d04f84dee23","<div></div>","SECTION 4","TRIAL DESIGN","NarrativeContent_11","4"
"ce67570d-9cbf-49b9-ad94-98ee1ed8a4ae","<div></div>","SECTION 4.1","Description of Trial Design","NarrativeContent_12","4.1"
"34b36270-40df-4bfd-ac4d-5c4c374fadfe","<div></div>","SECTION 4.1.1","Participant Input into Design","NarrativeContent_13","4.1.1"
"a0858f1d-77b7-46dd-9489-b8d1495132eb","<div></div>","SECTION 4.2","Rationale for Trial Design","NarrativeContent_14","4.2"
"ad68a758-0bd0-4a8c-a64b-353ffe46d1cb","<div></div>","SECTION 4.2.1","Rationale for Comparator","NarrativeContent_15","4.2.1"
"28c9dee8-e425-4975-8564-fd83fa9b05b8","<div></div>","SECTION 4.2.2","Rationale for Adaptive or Novel Trial Design","NarrativeContent_16","4.2.2"
"d0094441-339e-4ee0-ab32-5be41e97c54d","<div></div>","SECTION 4.2.3","Other Trial Design Considerations","NarrativeContent_17","4.2.3"
"48d21061-e38e-4ea1-b3cf-6db162ccb80e","<div></div>","SECTION 4.3","Access to Trial Intervention After End of Trial","NarrativeContent_18","4.3"
"a96781de-e738-47b6-8439-203672ab0a57","<div></div>","SECTION 4.4","Start of Trial and End of Trial","NarrativeContent_19","4.4"
"c4fed53f-a5bb-4151-91c4-f2b1924026a9","<div></div>","SECTION 5","TRIAL POPULATION","NarrativeContent_20","5"
"572f7681-18a9-4a65-bea6-e26a896936dd","<div></div>","SECTION 5.1","Selection of Trial Population","NarrativeContent_21","5.1"
"2e7d59aa-ef33-48c9-8594-3b1f0d356b38","<div></div>","SECTION 5.2","Rationale for Trial Population","NarrativeContent_22","5.2"
"263907d4-14bd-4f4f-b4b4-a5b3eeac6013","<div><p>Inclusion criteria are:</p>
<ul>
  <li>1. Something</li>
  <li>2. Something else</li>
</ul></div>","SECTION 5.3","Inclusion Criteria","NarrativeContent_23","5.3"
"340352f7-ef1c-485f-a43f-a54e03664055","<div><p>Exclusion criteria are:</p>
<ul>
  <li>1. Dont do this</li>
  <li>2. And don't do that</li>
</ul></div>","SECTION 5.4","Exclusion Criteria","NarrativeContent_24","5.4"
"4e5d9510-43fc-4e1e-972d-f6591250bbf1","<div></div>","SECTION 5.5","Lifestyle Considerations","NarrativeContent_25","5.5"
"5d9a6c31-974a-45a4-b293-21e4cb59171f","<div></div>","SECTION 5.5.1","Meals and Dietary Restrictions","NarrativeContent_26","5.5.1"
"17bd7855-6fc1-4091-ada5-985b1f30f349","<div></div>","SECTION 5.5.2","Caffeine, Alcohol, Tobacco, and Other Habits","NarrativeContent_27","5.5.2"
"10c7a979-c3db-4597-8918-3c09b6e0849c","<div></div>","SECTION 5.5.3","Physical Activity","NarrativeContent_28","5.5.3"
"1366e6fa-bdc9-41a8-878e-d7f8e9e6fb62","<div></div>","SECTION 5.5.4","Other Activity","NarrativeContent_29","5.5.4"
"50e8d3ea-dd1b-4108-878b-d3a06a42e7fb","<div></div>","SECTION 5.6","Screen Failures","NarrativeContent_30","5.6"
"e031a935-2a83-4f1c-9192-e3547e74151a","<div></div>","SECTION 6","TRIAL INTERVENTION AND CONCOMITANT THERAPY","NarrativeContent_31","6"
"aaedbb80-f5d8-4249-8d9d-20f92d06ffe9","<div></div>","SECTION 6.1","Description of Trial Intervention","NarrativeContent_32","6.1"
"4c178a7a-fe0f-48de-8c32-d912088db5f8","<div></div>","SECTION 6.2","Rationale for Trial Intervention","NarrativeContent_33","6.2"
"74dd07c7-7935-4a02-98ef-92fd6404cd97","<div></div>","SECTION 6.3","Dosing and Administration","NarrativeContent_34","6.3"
"7a1aeca2-31f0-49c6-bde0-bfe5e9839d1f","<div></div>","SECTION 6.3.1","Trial Intervention Dose Modification","NarrativeContent_35","6.3.1"
"8d43150a-5570-47c1-bb18-da0f5a996896","<div></div>","SECTION 6.4","Treatment of Overdose","NarrativeContent_36","6.4"
"a9629cab-58f9-4e97-82a5-670db7473dfd","<div></div>","SECTION 6.5","Preparation, Handling, Storage and Accountability","NarrativeContent_37","6.5"
"a159299a-5e65-4edb-9e5a-518aa80d6c84","<div></div>","SECTION 6.5.1","Preparation of Trial Intervention","NarrativeContent_38","6.5.1"
"1833e45f-d37c-4d88-b110-c5042c1ea2d2","<div></div>","SECTION 6.5.2","Handling and Storage of Trial Intervention","NarrativeContent_39","6.5.2"
"1286ea3c-077b-493e-9d89-be9980673537","<div></div>","SECTION 6.5.3","Accountability of Trial Intervention","NarrativeContent_40","6.5.3"
"f93fd330-cfbb-4e8a-8132-d20cb0c26931","<div></div>","SECTION 6.6","Participant Assignment, Randomisation and Blinding","NarrativeContent_41","6.6"
"fb5a0c6f-79ec-4324-876e-d8d62e6da032","<div></div>","SECTION 6.6.1","Participant Assignment","NarrativeContent_42","6.6.1"
"2e1437cb-6e9f-4bc1-8a57-653503f6e02a","<div></div>","SECTION 6.6.2","Randomisation","NarrativeContent_43","6.6.2"
"3da92d65-bd9a-4085-9c3c-2a2b2f956a4b","<div><p>Blinding and unblinding text here please</p></div>","SECTION 6.6.3","Blinding and Unblinding","NarrativeContent_44","6.6.3"
"deffb13d-2bc1-4036-9636-cdc92f11fb40","<div></div>","SECTION 6.7","Trial Intervention Compliance","NarrativeContent_45","6.7"
"0e4d4688-8a97-4802-9756-0aa9c2e8a6dc","<div></div>","SECTION 6.8","Concomitant Therapy","NarrativeContent_46","6.8"
"ef5d90b3-8c4f-4b70-a880-f308295b295b","<div></div>","SECTION 6.8.1","Prohibited Concomitant Therapy","NarrativeContent_47","6.8.1"
"9239b7ed-5c55-48ed-a548-d27042cbaefb","<div></div>","SECTION 6.8.2","Permitted Concomitant Therapy","NarrativeContent_48","6.8.2"
"8593ba66-f103-40b6-a389-47ed34e6c439","<div></div>","SECTION 6.8.3","Rescue Therapy","NarrativeContent_49","6.8.3"
"9e442484-f1e3-45e6-9698-5ab5cfc916c5","<div></div>","SECTION 6.8.4","Other Therapy","NarrativeContent_50","6.8.4"
"b3c08a16-b192-4922-b29a-e655ed68c269","<div></div>","SECTION 7","DISCONTINUATION OF TRIAL INTERVENTION AND PARTICIPANT WITHDRAWAL FROM TRIAL","NarrativeContent_51","7"
"85d77c28-bd6f-41d5-9b6c-b21be8ebade4","<div></div>","SECTION 7.1","Discontinuation of Trial Intervention","NarrativeContent_52","7.1"
"8badba95-e6b9-4303-bda5-6b4b504c144f","<div></div>","SECTION 7.1.1","Criteria for Permanent Discontinuation of Trial Intervention","NarrativeContent_53","7.1.1"
"c333522d-78b6-4d9f-9fa6-453affc344a6","<div></div>","SECTION 7.1.2","Temporary Discontinuation or Interruption of Trial Intervention","NarrativeContent_54","7.1.2"
"c7b598ea-7a36-43e7-9908-2a6ab5fb27e4","<div></div>","SECTION 7.1.3","Rechallenge","NarrativeContent_55","7.1.3"
"48577c62-c8ba-4b65-8d2d-284ddde67e72","<div></div>","SECTION 7.2","Participant Withdrawal from the Trial","NarrativeContent_56","7.2"
"defd0470-996e-4ba1-ac00-3eaf7df9affd","<div></div>","SECTION 7.3","Lost to Follow-Up","NarrativeContent_57","7.3"
"45f90815-6fda-421b-8cbc-24934c94005e","<div></div>","SECTION 7.4","Trial Stopping Rules","NarrativeContent_58","7.4"
"02c1e672-3eb2-44e5-b4d7-41f78dda23b8","<div></div>","SECTION 8","TRIAL ASSESSMENTS AND PROCEDURES","NarrativeContent_59","8"
"a6ba79d9-f908-4f8b-af6c-c74f500b5d81","<div></div>","SECTION 8.1","Screening/Baseline Assessments and Procedures","NarrativeContent_60","8.1"
"aff57a6d-14bf-4556-9919-fb0bc17adf5d","<div></div>","SECTION 8.2","Efficacy Assessments and Procedures","NarrativeContent_61","8.2"
"7b71cb11-a360-4468-b50c-cb7cd6835abf","<div></div>","SECTION 8.3","Safety Assessments and Procedures","NarrativeContent_62","8.3"
"d23d673d-3473-45be-ad37-199acd094766","<div></div>","SECTION 8.3.1","Physical Examination","NarrativeContent_63","8.3.1"
"a2493690-b0fa-4e91-8981-5b9dcd4215c9","<div></div>","SECTION 8.3.2","Vital Signs","NarrativeContent_64","8.3.2"
"42dd1d49-0137-43d3-ae55-6f9b71c0ae52","<div></div>","SECTION 8.3.3","Electrocardiograms","NarrativeContent_65","8.3.3"
"0de30c9a-50b8-48c7-9866-1065ac7eb7ac","<div></div>","SECTION 8.3.4","Clinical Laboratory Assessments","NarrativeContent_66","8.3.4"
"23eb9902-f73a-44e2-8d9b-f4f8d5eeb715","<div></div>","SECTION 8.3.5","Suicidal Ideation and Behaviour Risk Monitoring","NarrativeContent_67","8.3.5"
"1fcf153c-8b0c-4aa6-b405-305709a1319b","<div></div>","SECTION 8.4","Adverse Events and Serious Adverse Events","NarrativeContent_68","8.4"
"069a3a18-0d61-46e7-a94e-b1b78f4ddcbb","<div></div>","SECTION 8.4.1","Definitions of AE and SAE","NarrativeContent_69","8.4.1"
"cbca97c3-703b-4bee-a5bf-7feda79cf1cf","<div></div>","SECTION 8.4.2","Time Period and Frequency for Collecting AE and SAE Information","NarrativeContent_70","8.4.2"
"7251f590-3d6d-4f7c-9895-1797910189c0","<div></div>","SECTION 8.4.3","Identifying AEs and SAEs","NarrativeContent_71","8.4.3"
"e982d641-3bde-4f56-af4e-f8cfc97b7c81","<div></div>","SECTION 8.4.4","Recording of AEs and SAEs","NarrativeContent_72","8.4.4"
"038a6439-0a3f-48af-a7a1-d71373e38edd","<div></div>","SECTION 8.4.5","Follow-up of AEs and SAEs","NarrativeContent_73","8.4.5"
"8cb4f732-2358-4e34-a50c-6cb67b503595","<div></div>","SECTION 8.4.6","Reporting of SAEs","NarrativeContent_74","8.4.6"
"409b33b5-062b-44c1-b21b-c4098a3d01d2","<div></div>","SECTION 8.4.7","Regulatory Reporting Requirements for SAEs","NarrativeContent_75","8.4.7"
"d6445d40-c262-4f1d-9454-f69f25c77f5a","<div></div>","SECTION 8.4.8","Serious and Unexpected Adverse Reaction Reporting","NarrativeContent_76","8.4.8"
"3fdd9fa2-d70b-4254-9cac-620aa17f4fc1","<div></div>","SECTION 8.4.9","Adverse Events of Special Interest","NarrativeContent_77","8.4.9"
"3a055cef-72f5-4342-a725-581130ab8ad9","<div></div>","SECTION 8.4.10","Disease-related Events or Outcomes Not Qualifying as AEs or SAEs","NarrativeContent_78","8.4.10"
"c3f02c6c-a9d6-491d-b8fd-9fc62aae8017","<div></div>","SECTION 8.5","Pregnancy and Postpartum Information","NarrativeContent_79","8.5"
"ac938360-78ab-4a20-957f-02adfd607f25","<div></div>","SECTION 8.5.1","Participants Who Become Pregnant During the Trial","NarrativeContent_80","8.5.1"
"c02938c1-fb5a-4544-8a36-b2cd862b7a2e","<div></div>","SECTION 8.5.2","Participants Whose Partners Become Pregnant","NarrativeContent_81","8.5.2"
"678c465e-df53-4a3d-aa0b-05acf6e9da4b","<div></div>","SECTION 8.6","Medical Device Product Complaints for Drug/Device Combination Products","NarrativeContent_82","8.6"
"05c7f781-e025-43cd-bc83-4ac4f46703c6","<div></div>","SECTION 8.6.1","Definition of Medical Device Product Complaints","NarrativeContent_83","8.6.1"
"e7f06d3f-1e76-4a33-8b8f-0a17a154f909","<div></div>","SECTION 8.6.2","Recording of Medical Device Product Complaints","NarrativeContent_84","8.6.2"
"cc9e9b28-2a6b-48a0-a154-6268bf4103db","<div></div>","SECTION 8.6.3","Time Period and Frequency for Collecting Medical Device Product Complaints .","NarrativeContent_85","8.6.3"
"6b775246-1077-4c22-99d9-610be27e0102","<div></div>","SECTION 8.6.4","Follow-Up of Medical Device Product Complaints","NarrativeContent_86","8.6.4"
"8e3eac9a-b91c-4ba1-b6e8-93070a4b5cf4","<div></div>","SECTION 8.6.5","Regulatory Reporting Requirements for Medical Device Product Complaints","NarrativeContent_87","8.6.5"
"6868da3e-48d1-4a89-bd86-cdcfce06529c","<div></div>","SECTION 8.7","Pharmacokinetics","NarrativeContent_88","8.7"
"c423fa4d-2051-4618-ad6a-b55ce0ae7483","<div></div>","SECTION 8.8","Genetics","NarrativeContent_89","8.8"
"25126066-d07a-4c1a-a762-523f2604e923","<div></div>","SECTION 8.9","Biomarkers","NarrativeContent_90","8.9"
"98fbff1e-699e-436b-9a84-e0051a872205","<div></div>","SECTION 8.1","Immunogenicity Assessments","NarrativeContent_91","8.1"
"0f8feb29-83d9-4b54-af39-c40340fe6c0b","<div></div>","SECTION 8.1.1","Medical Resource Utilisation and Health Economics","NarrativeContent_92","8.1.1"
"f89c00ee-3655-432c-9d30-f9cc9cc17d57","<div></div>","SECTION 9","STATISTICAL CONSIDERATIONS","NarrativeContent_93","9"
"939ecd81-110e-4046-926b-7b8b4755e825","<div></div>","SECTION 9.1","Analysis Sets","NarrativeContent_94","9.1"
"e0e9d7d0-6432-4080-9b99-12168fdf2354","<div></div>","SECTION 9.2","Analyses Supporting Primary Objective(s)","NarrativeContent_95","9.2"
"450dfbb9-491d-4509-bdf3-f629361e4645","<div></div>","SECTION 9.2.1","Statistical Model, Hypothesis, and Method of Analysis","NarrativeContent_96","9.2.1"
"ee771311-e35d-4b34-9260-3791e63c10f6","<div></div>","SECTION 9.2.2","Handling of Intercurrent Events of Primary Estimand(s)","NarrativeContent_97","9.2.2"
"9d9788da-2912-4010-9fce-2525c71efad1","<div></div>","SECTION 9.2.3","Handling of Missing Data","NarrativeContent_98","9.2.3"
"b4a01248-2941-42be-be33-7541df8862cc","<div></div>","SECTION 9.2.4","Sensitivity Analysis","NarrativeContent_99","9.2.4"
"a28e2434-5cfd-4aae-8c21-df1e664e683e","<div></div>","SECTION 9.2.5","Supplementary Analysis","NarrativeContent_100","9.2.5"
"eac17ee3-29c4-4f57-9e84-cbfd4b2956b4","<div></div>","SECTION 9.3","Analysis Supporting Secondary Objective(s)","NarrativeContent_101","9.3"
"64fa71fe-d0ac-45b8-9c90-b30edb0a50da","<div></div>","SECTION 9.4","Analysis of Exploratory Objective(s)","NarrativeContent_102","9.4"
"081383d2-83cb-431e-9d6f-ac8a31019775","<div></div>","SECTION 9.5","Safety Analyses","NarrativeContent_103","9.5"
"328cbb55-f875-494d-ab40-ee2d0f88965a","<div></div>","SECTION 9.6","Other Analyses","NarrativeContent_104","9.6"
"f63a2b7e-b6f3-4292-8291-686cbbf6995c","<div></div>","SECTION 9.7","Interim Analyses","NarrativeContent_105","9.7"
"01578f69-40ff-4810-9120-d11866c92828","<div></div>","SECTION 9.8","Sample Size Determination","NarrativeContent_106","9.8"
"d3e37c82-492a-45e5-a9c6-ba58db9dc58f","<div></div>","SECTION 9.9","Protocol Deviations","NarrativeContent_107","9.9"
"bec9c747-0b75-4150-8964-528c87363587","<div></div>","SECTION 10","GENERAL CONSIDERATIONS: REGULATORY, ETHICAL, AND TRIAL OVERSIGHT","NarrativeContent_108","10"
"1ad5e52d-b344-417b-8662-5cc9a3f0088c","<div></div>","SECTION 10.1","Regulatory and Ethical Considerations","NarrativeContent_109","10.1"
"718bca5f-d7ef-4616-898f-1ae1b30013dd","<div></div>","SECTION 10.2","Committees","NarrativeContent_110","10.2"
"2a947728-4e4e-4dd6-a2bb-95f830f5a74f","<div></div>","SECTION 10.3","Informed Consent Process","NarrativeContent_111","10.3"
"e880e40a-5659-465a-98f6-d1e87d9cbf17","<div></div>","SECTION 10.4","Data Protection","NarrativeContent_112","10.4"
"95e797af-84c4-4d55-aad4-2d91faabe7b4","<div></div>","SECTION 10.5","Early Site Closure or Trial Termination","NarrativeContent_113","10.5"
"c0b462ec-2f40-4036-b1b5-d93073b85e66","<div></div>","SECTION 11","GENERAL CONSIDERATIONS: RISK MANAGEMENT AND QUALITY ASSURANCE","NarrativeContent_114","11"
"1644c15d-372d-4830-97ce-de6429c5595c","<div></div>","SECTION 11.1","Quality Tolerance Limits","NarrativeContent_115","11.1"
"4c4e7745-174a-486b-a449-f88c760d72ca","<div></div>","SECTION 11.2","Data Quality Assurance","NarrativeContent_116","11.2"
"9d72ae3e-c05b-4fd1-b3a8-1708e77f4c1b","<div></div>","SECTION 11.3","Source Data","NarrativeContent_117","11.3"
"b612356c-0660-4011-ad1d-22a3e91efe3b","<div></div>","SECTION 12","APPENDIX: ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS - DEFINITIONS, SEVERITY, AND CAUSALITY","NarrativeContent_118","12"
"1b419642-cf3e-41e9-a3d0-a329b52cc3d0","<div></div>","SECTION 12.1","Further Details and Clarifications on the AE Definition","NarrativeContent_119","12.1"
"cb95a780-f3aa-404e-acd1-69fe5cf55387","<div></div>","SECTION 12.2","Further Details and Clarifications on the SAE Definition","NarrativeContent_120","12.2"
"20304a7c-f055-4abf-8acb-03a931d3ff65","<div></div>","SECTION 12.3","Severity","NarrativeContent_121","12.3"
"f0af8b1e-1b05-4205-8fe7-44c02d59ebc7","<div></div>","SECTION 12.4","Causality","NarrativeContent_122","12.4"
"021bc2df-0cc2-45b0-8283-4b118de4903e","<div></div>","SECTION 13","APPENDIX: DEFINITIONS AND SUPPORTING OPERATIONAL DETAILS","NarrativeContent_123","13"
"da3c916b-b4b2-4439-8dcf-d38ab8b17f62","<div></div>","SECTION 13.1","Contraception and Pregnancy Testing","NarrativeContent_124","13.1"
"9ce2c818-05b0-471e-ae1a-71e89e67d121","<div></div>","SECTION 13.1.1","Definitions Related to Childbearing Potential","NarrativeContent_125","13.1.1"
"86ee6b5f-58a2-43a8-b837-5f6a9c61fb69","<div></div>","SECTION 13.1.2","Contraception","NarrativeContent_126","13.1.2"
"ab4fe286-c571-4aa3-ae6a-7b1c53e8f7a8","<div></div>","SECTION 13.1.3","Pregnancy Testing","NarrativeContent_127","13.1.3"
"86021439-ef11-41d4-a223-ffdd7f121bf3","<div></div>","SECTION 13.2","Clinical Laboratory Tests","NarrativeContent_128","13.2"
"bfb9cccc-fe93-4453-b537-64b1f0929695","<div></div>","SECTION 13.3","Country/Region-Specific Differences","NarrativeContent_129","13.3"
"52fffffd-368c-4b90-a904-dcbf04c61763","<div></div>","SECTION 13.4","Prior Protocol Amendments","NarrativeContent_130","13.4"
"b6a37374-c8ef-48fc-87d5-517e1a7eefe0","<div></div>","SECTION 14","APPENDIX: GLOSSARY OF TERMS","NarrativeContent_131","14"
"0c93abd4-3118-4bc9-a011-b8f79b838bce","<div></div>","SECTION 15","APPENDIX: REFERENCES","NarrativeContent_132","15"
